Calsed (amrubicin) 50 mg 1 vial
Product Code :
Availability : 10
Basic information on Amrubicin for lung cancer
Active component: amrubicin hydrochloride 50 mg
Application: treatment of lung cancer.
Dosage and administration: follow the instructions of the attending physician.
Contraindications and precautions: strictly follow the dosage. In case of complications, discontinue the drug treatment.
Amrubicin is a third-generation lung cancer medicine from Japan. The drug is distributed in Japan since 2005 by Nippon Kayaku.
Pharmacodynamics of Amrubicin.
The anthracycline glycoside group of antibiotics, including amrubicin, is a group of potent anti-cancer agents with strong activity against both solid tumors and hematological malignancies. Amrubicin is a derivative of 9-aminoanthracycline and contributes to the inhibition of cell growth by stabilizing protein-DNA complexes, followed by double-stranded DNA breaks, which are mediated by the enzyme topoisomerase II
The mechanism of action of Amrubicin.
As anthracycline, amrubicin has antimitotic and cytotoxic activity through various mechanisms of action. Amrubicin has been found to form complexes with DNA by intercalation between base pairs and inhibits the activity of the enzyme topoisomerase II by stabilizing the DNA-topoisomerase II complex, which prevents the ligation-re-polymerization reaction, which usually catalyzes the topoisomerase II
Toxicity of Amrubicin
Based on acute toxicity studies of intravenous doses, the lethal dose of up to 50% of animals was estimated at 42 mg / kg in mice, 14 mg / kg in rats and 4 mg / kg for dogs
Clinical trials and Research on Amrubicin.
The drug has been studied in numerous studies in Japan and in the west. You can check at lease several studies on this medicine:
- The article “Pharmacokinetics of amrubicin in patients with lung cancer with impaired liver function” (Pharmacokinetics of the amrubicin in lung cancer patients with impaired hepatic function) provides a detailed study of the pharmacokinetics of the drug and its methods for the treatment of specific diseases.
- The same drug is prescribed as an orphan drug by the US Department of Health (FDA) for the treatment of lung cancer - you can find relevant information here (Amrubicin Receives FDA orphan drug status).
- Professors Kurata T, Okamoto I, Tamura K, Fukuoka M conducted a fundamental collective study of the efficacy and methods of using this drug in their monograph (Amrubicin for non-small-cell lung cancer).
Related articles and information.
We are here to help, please feel free to ask any question. You can also check the following articles related to oncology and cancer treatment in Japan in our blog below: